Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
RMD Open. 2021;7(3):e001838
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
RMD Open. 2021;7(3):e001838
Ann Rheum Dis. 2021 Jul 28:annrheumdis-2021-220651
N Engl J Med 2021;385:1280–91 doi: 10.1056/NEJMoa2033617
Patients receiving ozanimod displayed a significant improvement in clinical response and all secondary endpoints during both the 10-week induction and 52-week maintenance study periods. Percentage of patients achieving clinical remission at Weeks 10 and 52 was the primary endpoint.
RMD Open. 2021;7(2):e001621.
Clin Rheumatol. 2021. Epub ahead of print doi: 10.1007/s10067-021-05853-x
Arthritis Rheumatol. 2021;73(7):1155–66
Rheumatology (Oxford). 2021;60(7):3209–21
Auto Immun Highlights. 2021;12(1):8.
Rheumatol Ther. 2021;8(2):903–919
Clin Rheumatol. 2021 Jun 16. DOI: 10.1007/s10067-021-05815-3